State-of-the Art Facility Will Focus on Developing New Treatments for Eye Diseases
Suzhou, China, October 13, 2021. A Grand Opening Ceremony for Eluminex Biosciences (Suzhou) Limited was held to celebrate the completion of its 23000 ft2 global Headquarters and R&D Center in BioBAY, Suzhou Industrial Park (SIP), Suzhou. More than 100 honorable guests of SIP, Dushu Lake Science and Education Innovation District, BioBAY, the investors and business partners were in attendance to celebrate the historical moment of the company. Dr. Jinzhong Zhang, Co-founder, Chairman and CEO of Eluminex, led the ceremony and extended a warm welcome to all the guests. He said, “Eluminex has been growing bigger and faster under the tremendous support of SIP, BioBAY and the investors over the last year. With the excellent business environment and ecosystem in BioBAY, Eluminex shall be able to take advantage of the rapid growth of China’s biopharmaceutical industry and continue to make great achievements.” Dr. Charles Semba, Chief Medical Officer of the company, representing the US-based team members, conveyed his congratulations and excitement for the establishment of Eluminex’s new global campus from the San Francisco Bay Area through live video. He believes that the new facility will support Eluminex’s mission in treating vision-threatening diseases for patients in China and around the world. Mr. Stephen Lin, Partner of Lilly Asia Ventures, on behalf of the Board of Directors, expressed his confidence in Eluminex and pledged full support for the future growth of Eluminex. Mr. Ni Qian, Vice Chairman of the SIP Administrative Committee stated, “Biopharmaceuticals is one of the most vibrant industries in the world today. SIP initiated the deployment early in 2006, providing great support to the development of the industry in Suzhou.” He added, “SIP will provide prominent support to Eluminex and assist Eluminex to become an innovative and ophthalmology-focusing biotech company of international caliber.”
About Eluminex Biosciences
Eluminex Biosciences is a privately-held clinical-stage biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. Eluminex is devoted towards innovating the next generation of first-in-class or best-in-class ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. In addition to the biosynthetic cornea (EB-301), Eluminex has developed a pipeline of next generation protein therapeutics for retinal diseases (EB-101, EB-102, EB-105, and EB-107) including age-related macular degeneration, macular edema, and diabetic retinopathy; these assets are wholly owned and developed by Eluminex. The Eluminex global headquarters and research and development center are located in Suzhou BioBay Industrial Park, China with a US-subsidiary located in the San Francisco Bay Area. Eluminex is supported by three premiere global life science venture funds: Lilly Asia Ventures, Hill House Capital, and Quan Capital.
For more information, please visit www.eluminexbio.com.
Contact for Investors/Media:
Zhenze John Hu, PhD, MPD